Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Special Topic

Management of liver diseases during the pandemic of coronavirus disease-19

Ju-Yeon Cho, Soon Sun Kim, Young-Sun Lee, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim

Clin Mol Hepatol. 2020;26(3):243-250. Published online June 23, 2020

Web of Science 8 Crossref 7

DOI: https://doi.org/10.3350/cmh.2020.0111

Reviews

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2020;26(3):251-260. Published online March 19, 2020

Web of Science 38 Crossref 41

DOI: https://doi.org/10.3350/cmh.2020.0018

Novel biomarkers for the management of chronic hepatitis B

Takako Inoue, Yasuhito Tanaka

Clin Mol Hepatol. 2020;26(3):261-279. Published online June 15, 2020

Web of Science 70 Crossref 73

DOI: https://doi.org/10.3350/cmh.2020.0032

Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis

Le Thi Thanh Thuy, Hoang Hai, Norifumi Kawada

Clin Mol Hepatol. 2020;26(3):280-293. Published online June 4, 2020

Web of Science 11 Crossref 12

DOI: https://doi.org/10.3350/cmh.2020.0037

Fecal microbiota transplantation in alcohol related liver diseases

Saggere Muralikrishna Shasthry

Clin Mol Hepatol. 2020;26(3):294-301. Published online June 23, 2020

Web of Science 19 Crossref 23

DOI: https://doi.org/10.3350/cmh.2020.0057

Editorials

Is liver biopsy still useful in the era of non-invasive tests?

Tae Seop Lim, Ja Kyung Kim

Clin Mol Hepatol. 2020;26(3):302-304. Published online July 1, 2020

Web of Science 10 Crossref 11

DOI: https://doi.org/10.3350/cmh.2020.0081

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma

Sojung Han, Do Young Kim

Clin Mol Hepatol. 2020;26(3):305-308. Published online July 1, 2020

Web of Science 5 Crossref 5

DOI: https://doi.org/10.3350/cmh.2020.0096

Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?

So Yeon Kim

Clin Mol Hepatol. 2020;26(3):309-311. Published online June 15, 2020

Web of Science 5 Crossref 5

DOI: https://doi.org/10.3350/cmh.2020.0061

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Byoung Kuk Jang

Clin Mol Hepatol. 2020;26(3):312-314. Published online July 1, 2020

Crossref 2

DOI: https://doi.org/10.3350/cmh.2020.0099

Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?

Jung Hee Kim, Dong Hyun Sinn

Clin Mol Hepatol. 2020;26(3):315-317. Published online June 23, 2020

Crossref 1

DOI: https://doi.org/10.3350/cmh.2020.0084

Original Articles

Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years

Young Chang, Jun Il Kim, Bora Lee, Sang Gyune Kim, Min Jung Jung, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Jeong-Ju Yoo

Clin Mol Hepatol. 2020;26(3):318-327. Published online May 25, 2020

Web of Science 18 Crossref 18

DOI: https://doi.org/10.3350/cmh.2019.0019n

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment

Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim

Clin Mol Hepatol. 2020;26(3):328-339. Published online May 28, 2020

Web of Science 30 Crossref 30

DOI: https://doi.org/10.3350/cmh.2019.0049n

Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging

Sunyoung Lee, Seung-seob Kim, Dong ryul Chang, Hyerim Kim, Myeong-Jin Kim

Clin Mol Hepatol. 2020;26(3):340-351. Published online June 4, 2020

Web of Science 41 Crossref 45

DOI: https://doi.org/10.3350/cmh.2020.0004

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn

Clin Mol Hepatol. 2020;26(3):352-363. Published online May 28, 2020

Web of Science 3 Crossref 4

DOI: https://doi.org/10.3350/cmh.2019.0044n

Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir

Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2020;26(3):364-375. Published online May 29, 2020

Web of Science 24 Crossref 21

DOI: https://doi.org/10.3350/cmh.2020.0012

Letters to the Editor

How does low-level viremia affect the prognosis of patients with chronic hepatitis B?

Hye Won Lee, Beom Kyung Kim

Clin Mol Hepatol. 2020;26(3):376-377. Published online June 11, 2020

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2020.0121

Macro-aspartate aminotransferase in a healthy woman

Maria Lorubbio, Agostino Ognibene, Benedetta Salvadori, Alessandra Fanelli, Giacomo Laffi

Clin Mol Hepatol. 2020;26(3):378-381. Published online June 23, 2020

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2020.0069

Viewed By 5294	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5240	MAFLD: How is it different from NAFLD?
Viewed By 5140	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3855	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3793	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Previous issues